Replies to post #231141 on Amarin Corp Plc (AMRN)

[biotechtrader2020]

>Sales reps bring in more than they cost or there would be no sales reps. Commercials are advertising. Advertising brings in more money than it costs or no one would advertise.

Not necessarily true. Many companies like SGYP had sales reps and spent on advertising and it didn't do jack shit to their profitability as those companies went bankrupt.

However, this gloom and doom is not applicable to AMRN. Sales are showing a healthy uptick and will only get better with expanded label.

While I don't agree with you comment on sales reps and Ads in general (it is not a certainty), I agree that it is highly relevant in AMRN's case and they will be profitable.(AMRN will be a successful growth story. But I still think that they will get a good offer and some other BP will be profiting from Vascepa's sales ramp).

[tmac20]

Simple stuff but if you haven’t been in biz maybe you are unaware of how it works.

Just making a point that sales will need to ramp up if GIA is the strategy.

I just hope this management is smart enough to recognize a good offer for where they are in the process. 800 sales reps for 1 drug is going to be an expensive rollout.

Why is it everyone on this board thinks they know everything (i.e. I haven't been in "biz") about everyone else? Where were you a CEO? Did you own the company? Did you sell it? Was it based on a multiple of EBITDA?